2. Клинические рекомендации. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Российское кардиологическое общество при участии Ассоциации сердечно-сосудистых хирургов России. 2020. Доступ: http://cr.rosminzdrav.ru/#!/schema/135 (датаобращения – 01.11.2020). [Clinical guidelines. Acute myocardial infarction with ST segmentelevation electrocardiogram. Russian Society of Cardiology with the participation of the Associationof Cardiovascular Surgeons of Russia. 2020. URL: http://cr.rosminzdrav.ru/#!/schema/135 (date ofaccess – 01.11.2020).

3. Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplatelet therapy incoronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelettherapy in coronary artery disease of the European Society of Cardiology (ESC) and of the EuropeanAssociation for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018; 39(3): 213–60. doi: 10.1093/eurheartj/ehx419.

4. Gibson C.M., Mehran R., Bode C. et al. Prevention of bleeding in patients with atrial fibrillationundergoing PCI. N Engl J Med. 2016; 375: 2423–34. doi: 10.1056/NEJMoa1611594.

5. Cannon C.P., Bhatt D.L., Oldgren J. et al.; DUAL RE-Steering Committee PCI and Investigators.Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017; 377:1513–24. doi: 10.1056/NEJMoa1708454.

6. Lopes R.D., Heizer G., Aronson R. et al. for the AUGUSTUS Investigators. Antithrombotic therapyafter acute coronary syndrome or PCI in atrial fibrillation. NEJM. 2019; 380: 1509–24. doi: 10.1056/NEJMoa1817083.

7. Lopes R.D., Hong H., Harskamp R.E. et al. Safety and efficacy of antithrombotic strategiesin patients with atrial fibrillation undergoing percutaneous coronary intervention: a networkmeta-analysis of randomized controlled trials. JAMA Cardiol. 2019; 4(8): 747–55. doi: 10.1001/jamacardio.2019.1880.

8. Yusuf S., Zhao F., Mehta S.R. et al. Effects of clopidogrel in addition to aspirin in patients withacute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494–502. doi:10.1056/NEJMoa010746.

9. Wiviott S.D., Braunwald E., McCabe C.H. et al. Prasugrel versus clopidogrel in patients with acutecoronary syndromes. N Engl J Med. 2007; 357: 2001–15. doi: 10.1056/NEJMoa0706482.

10. Wallentin L., Becker R.C., Budaj A. et al. Ticagrelor versus clopidogrel in patients with acutecoronary syndromes. N Engl J Med. 2009; 361: 1045–57. doi: 10.1056/NEJMoa0904327.

11. Mehta S.R., Yusuf S., Peters R.J. et al. Effects of pretreatment with clopidogrel and aspirin followedby long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CUREstudy. Lancet. 2001; 358: 527–33. doi: 10.1016/s0140-6736(01)05701-4.

12. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention ofvascular disease: collaborative meta-analysis of individual participant data from randomised trials.Lancet. 2009; 373: 1849–60. doi: 10.1016/S0140-6736(09)60503-1.

13. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials ofantiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.BMJ. 2002; 324(7329): 71–86. doi: 10.1136/bmj.324.7329.71.

14. Steg P.G., James S., Harrington R.A. et al.; PLATO Study Group. Ticagrelor versusclopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusionwith primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes(PLATO) trial subgroup analysis. Circulation. 2010; 122(21): 2131–41. doi: 10.1161/CIRCULATIONAHA.109.927582.

15. Montalescot G., Wiviott S.D., Braunwald E. et al. Prasugrel compared with clopidogrel in patientsundergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITONTIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373: 723–31. doi: 10.1016/S0140-6736(09)60441-4.

16. http://grls.rosminzdrav.ru/ (date of access – 01.11.2020).

17. Mega J.L., Braunwald E., Wiviott S.D. et al.; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxabanin patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366: 9–19. doi: 10.1056/NEJMoa1112277.

18. Рабочая группа по двойной антитромбоцитарной терапии при ишемической болезни сердцаЕвропейского общества кардиологов (ЕОК, ESC) и Европейской ассоциации кардио-торакальной хирургии (EACTS). Двойная антитромбоцитарная терапия при ишемическойболезни сердца: обновленная версия 2017 года. Российский кардиологический журнал. 2018;8: 113–163.

19. Mauri L., Kereiakes D.J., Yeh R.W. et al.; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371: 2155–66. doi: 10.1056/ NEJMoa1409312.

20. Udell J.A., Bonaca M.P., Collet J.P. et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016; 37: 390–99. doi: 10.1093/ eurheartj/ehv443.

21. Costa F., Van Klaveren D., Feres F. et al.; PRECISE-DAPT Study Investigators. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol. 2019; 73(7): 741–54. doi: 10.1016/j.jacc.2018.11.048.

22. Bonaca M.P., Bhatt D.L., Steg P.G. et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: Insights from PEGASUS-TIMI 54. Eur Heart J. 2016; 37: 1133–42. doi: 10.1093/eurheartj/ehv531.

23. Bonaca M.P., Bhatt D.L., Cohen M. et al.4 PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791–800. doi: 10.1056/NEJMoa1500857.

24. Eikelboom J.W., Connolly S.J., Bosch J. et al.; COMPASS investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377: 1319-1330. doi: 10.1056/ NEJMoa1709118.